KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Short-term Investments (2016 - 2026)

NovoCure's Short-term Investments history spans 13 years, with the latest figure at $344.5 million for Q1 2026.

  • On a quarterly basis, Short-term Investments fell 57.04% to $344.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $344.5 million, a 57.04% decrease, with the full-year FY2025 number at $9.8 million, down 98.76% from a year prior.
  • Short-term Investments hit $344.5 million in Q1 2026 for NovoCure, up from $9.8 million in the prior quarter.
  • Over the last five years, Short-term Investments for NVCR hit a ceiling of $854.1 million in Q4 2022 and a floor of $231000.0 in Q3 2022.
  • Historically, Short-term Investments has averaged $354.5 million across 5 years, with a median of $344.5 million in 2026.
  • The widest YoY moves for Short-term Investments: up 331669.7% in 2023, down 99.91% in 2023.
  • Tracing NVCR's Short-term Investments over 5 years: stood at $854.1 million in 2022, then decreased by 21.58% to $669.8 million in 2023, then grew by 18.86% to $796.1 million in 2024, then tumbled by 98.76% to $9.8 million in 2025, then skyrocketed by 3400.07% to $344.5 million in 2026.
  • Business Quant data shows Short-term Investments for NVCR at $344.5 million in Q1 2026, $9.8 million in Q4 2025, and $2.5 million in Q3 2025.